NurExone Biologic Inc. (TSX.V: NRX) (OTCQB: NRXBF) is set to present its exosome-based therapeutic platform and outline its U.S. manufacturing and commercialization initiatives at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference, scheduled for Sept. 9-10 in New York City. The company announced that its co-founder and chairman, Yoram Drucker, will address investors and participate in one-on-one meetings during the event.
The presentation comes as NurExone advances its preclinical programs, with a focus on regenerative therapies for central nervous system injuries. The company’s lead candidate, ExoPTEN, has demonstrated strong preclinical potential in treating acute spinal cord and optic nerve damage. By highlighting its pipeline and U.S. initiatives, NurExone aims to attract investor interest as it prepares for potential clinical development.
NurExone’s participation in the conference is a strategic move to increase visibility among institutional investors and life sciences stakeholders. The company’s exosome-based platform, including its Exo-Top delivery system, is designed to provide minimally invasive targeted therapies, which could offer significant advantages over current treatment options. With a North American strategy anchored by its Exo-Top platform, NurExone is positioning itself to capitalize on the growing demand for advanced regenerative medicines.
The conference, hosted by Moody Capital Solutions, is dedicated to disruptive growth and life sciences, providing a venue for emerging companies to connect with potential partners and investors. For NurExone, this is an opportunity to articulate its vision of supplying quality exosomes and targeted delivery systems while advancing its product pipeline.
The company’s focus on central nervous system injuries addresses a significant unmet medical need. Spinal cord and optic nerve damage often lead to permanent disability, and current treatments are limited. ExoPTEN, NurExone’s lead candidate, has shown promise in preclinical studies, suggesting it could potentially restore function by promoting nerve regeneration. The company’s broader platform aims to leverage the natural properties of exosomes for targeted drug delivery, which could improve efficacy and reduce side effects compared to conventional therapies.
NurExone’s U.S. initiatives are part of its strategy to establish a strong foothold in the North American market. By showcasing its manufacturing capabilities and commercialization plans, the company is signaling its readiness to transition from preclinical research to clinical trials. This progression is critical for biotech firms, as successful clinical development can lead to regulatory approval and market entry.
Investors attending the conference will have the opportunity to engage directly with management and gain insights into NurExone’s technological advancements and business strategy. The company’s participation underscores its commitment to transparency and its proactive approach to building shareholder value.
For more details on the press release, visit https://ibn.fm/o2PD0.
